{"nctId":"NCT01475825","briefTitle":"A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol","startDateStruct":{"date":"2011-12","type":"ACTUAL"},"conditions":["Hypercholesterolemia","Heterozygous Familial"],"count":309,"armGroups":[{"label":"Regimen A: Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: mipomersen sodium 200 mg"]},{"label":"Regimen A: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Regimen B: Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: mipomersen sodium 70 mg"]},{"label":"Regimen B: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"mipomersen sodium 200 mg","otherNames":["Kynamro (ISIS 301012)"]},{"name":"Placebo","otherNames":[]},{"name":"mipomersen sodium 70 mg","otherNames":["Kynamro (ISIS 301012)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of severe hypercholesterolemia (LDL-C ≥300 mg/dL (7.77 mmol/L) or LDL-C ≥200 mg/dL (5.18 mmol/L) with documented coronary heart disease (CHD) or CHD risk equivalents, or diagnosis of Heterozygous Familial Hypercholesterolemia and LDL-C ≥160 mg/dL (4.14 mmol/L) and \\<200 mg/dL (5.18 mmol/L))\n* On stable, maximally tolerated, statin therapy for at least 12 weeks or if statin intolerant, on at least 1 medication from another class of hypolipidemic agents (i.e., bile acid sequestrants, niacin/nicotinic acid, cholesterol absorption inhibitors, fibrates).\n* On stable, low fat diet for 12 weeks\n* Body mass index (BMI) ≤40 kg/m2 and stable weight for \\> 6 weeks\n\nExclusion Criteria:\n\n* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, blood disorders, liver disease, cancer, digestive disorders, Type I diabetes, or uncontrolled Type II diabetes\n* Apheresis within 3 months prior to Screening or expected to start apheresis during the treatment phase","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline To Primary Endpoint Visit (PET) In LDL-C In Cohort 1","description":"The percent change from baseline to PET in LDL-C was measured in Cohort 1, which included participants with severe heterozygous familial hypercholesterolemia (HeFH). Severe HeFH was defined as LDL-C levels ≥200 mg/deciliter (dL) plus the presence of coronary heart disease (CHD)/risk equivalents or LDL-C levels ≥300 mg/dL regardless of the presence of CHD/risk equivalents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.17","spread":"5.653"},{"groupId":"OG001","value":"-6.77","spread":"6.749"},{"groupId":"OG002","value":"-22.96","spread":"5.362"},{"groupId":"OG003","value":"-10.62","spread":"5.765"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline To PET In LDL-C In Cohort 2","description":"The percent change from baseline to PET in LDL-C was measured in Cohort 2, which included participants with HeFH with LDL-C levels ≥160 mg/dL and \\<200 mg/dL, plus the presence of CHD/risk equivalents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.20","spread":"8.927"},{"groupId":"OG001","value":"-9.25","spread":"10.621"},{"groupId":"OG002","value":"-43.60","spread":"8.342"},{"groupId":"OG003","value":"-13.57","spread":"9.066"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 1","description":"The percent change from baseline to PET in Apo B was measured in participants in Cohort 1 with HeFH during the Blinded Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.14","spread":"5.058"},{"groupId":"OG001","value":"-2.83","spread":"6.115"},{"groupId":"OG002","value":"-21.43","spread":"4.861"},{"groupId":"OG003","value":"-7.28","spread":"5.309"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline To PET In Apolipoprotein B (Apo B) In Cohort 2","description":"The percent change from baseline to PET in Apo B was measured in participants in Cohort 2 with HeFH during the Blinded Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.76","spread":"7.309"},{"groupId":"OG001","value":"-6.67","spread":"8.758"},{"groupId":"OG002","value":"-36.34","spread":"7.039"},{"groupId":"OG003","value":"-3.77","spread":"8.109"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 1","description":"The percent change from baseline to PET in Lipoprotein A1 was measured in participants in Cohort 1 with HeFH during the Blinded Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.84","spread":"7.870"},{"groupId":"OG001","value":"-16.85","spread":"9.959"},{"groupId":"OG002","value":"-27.18","spread":"5.497"},{"groupId":"OG003","value":"-10.08","spread":"5.992"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline To PET in Lipoprotein (a) In Cohort 2","description":"The percent change from baseline to PET in Lipoprotein A1 was measured in participants in Cohort 2 with HeFH during the Blinded Treatment Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.41","spread":"10.002"},{"groupId":"OG001","value":"-11.86","spread":"11.871"},{"groupId":"OG002","value":"-35.56","spread":"11.846"},{"groupId":"OG003","value":"18.79","spread":"15.271"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":104},"commonTop":["Influenza like illness","Alanine aminotransferase increased","Aspartate aminotransferase increased","Nasopharyngitis","Injection site erythema"]}}}